Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.320
+0.030 (2.33%)
May 21, 2026, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Lineage Cell Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.14. The average 1-year stock price forecast is 289.39% higher than the current stock price, while the lowest is $3.00 (+127.27%) and the highest is $9.00 (+581.82%).
Price Target: $5.14 (+289.39%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 | Strong Buy | Maintains | $3 | +127.27% | May 4, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +581.82% | Apr 28, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $3 → $4 | Strong Buy | Maintains | $3 → $4 | +203.03% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +581.82% | Mar 24, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 → $3 | Strong Buy | Maintains | $2 → $3 | +127.27% | Mar 6, 2026 |
Financial Forecast
Revenue This Year
27.87M
from 14.56M
Increased by 91.49%
Revenue Next Year
15.00M
from 27.87M
Decreased by -46.19%
EPS This Year
-0.06
from -0.28
EPS Next Year
-0.09
from -0.06
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 60.8M | 27.8M | ||||||
| Avg | 27.9M | 15.0M | ||||||
| Low | 8.3M | 5.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 317.7% | -0.4% | ||||||
| Avg | 91.5% | -46.2% | ||||||
| Low | -43.2% | -81.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.12 | 0.02 | ||||||
| Avg | -0.06 | -0.09 | ||||||
| Low | -0.14 | -0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.